LEVELS OF PROINFLAMMATORY MARKERS IN STEMI PATIENTS IN DIFFERENT TYPES OF DUAL ANTIPLATELET THERAPY

Aim. To assess levels of interleukin-6 (IL-6) and cardial infarction patients receiving clopidogrel or ticaC-reactive protein (CRP) in ST-segment elevation myogrelor in the in-hospital period.

Methods. 80 patients with STEMI were included in the study. All patients received a loading dose of aspirin (250 mg) and clopidogrel (600 mg) in the ambulance. All patients underwent urgent coronary angiography with the further stenting of the infarct-related artery with bare-metal stents. All patients were assigned to two groups using simple random sampling. Group 1 patients received a daily maintenance dose of clopidogrel 75 mg. Group 2 patients received a maintenance dose of ticagrelor 90 mg twice daily. Plasma levels of IL-6 and CRP were measured on day 1 after the hospital admission before replacing clopidogrel to ticagrelor and on day 7 after switching clopidogrel to ticagrelor (day 8 of the in-hospital period).

Results. Levels of CRP and IL-6 in the early period after STEMI in the groups of patients receiving clopidogrel and ticagrelor were similar (p=0.82 vs. p=0.27, respectively). On day 8, CRP levels in the clopidogrel group were significantly higher than CRP levels in the ticagrelor group on day 8 (25.3 (4.6; 46.4) ml / l vs. 17.5 (4.6; 20.9) mg / l, respectively (p = 0.04). The level of IL-6 in the clopidogrel group on day 8 was significantly higher than the level of IL-6 on day 8 in the ticagrelor group (7.03 (2.7; 11.3) pg / mL, vs. 2.8 (1.8; 4.2) pg / mL, respectively (p = 0.01).

Conclusion. Levels of proinflammatory markers were significantly lower in the ticagrelor group on day 8 after STEMI compared to the clopidogrel group.

1. Ichikawa S., Tsukahara K., Minamimoto Y., Kimura Y., Matsuzawa Y., Maejima N. et al. Pharmacodynamic assessment of platelet reactivity after a loading dose of prasugrel or clopidogrel in patients with ST-segment elevation myocardial infarction. Circ J. 2016;80(12):2520-2527. DOI: 10.1253/circj.CJ-16-0513

2. Плескановская C.A., Тачмухаммедова A.X. Влияние отвара MT на популяционный состав лейкоцитов, численность и морфологию тромбоцитов периферической крови условно здоровых лиц invitro. Молодой ученый. 2015;12:86-91. [Pleskanovskaya S.A., Tashmukhamedova A.H. the influence of decoction of MT at the population composition of white blood cells, the number and morphology of platelets of peripheral blood of healthy individuals in vitro./ the Young scientist. 2015;12: 86-91. (In Russ)].

3. Oh M., Lee C.W., Lee H.S., Chang M., Ahn J.M., Park D.W. et al. Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation. Clin Cardiol. 2016;39 (11):646652. doi: 10.1002/clc.22575.

4. Барбараш О.Л., Кашталап B.B. Выявление латентного некоронарного атеросклероза у пациентов с острым коронарным синдромом. Есть ли смысл? Комплексные проблемы сердечно-сосудистых заболеваний. 2012;(1):12-16. [Barbarash O.L., Kashtalap V.V. Diagnosis of latent forms of non-coronary atherosclerosis in acute coronary syndrome patients. Is there any practical sense? Complex Issues of Cardiovascular Diseases. 2012;(1):12-16. (In Russ)].

5. Zhang T., Wang Z., Xiao W. A meta-analysis of interleukin-6 -572G'C polymorphism and coronary heart disease susceptibility. Cardiol J. 2017;24(1):107-110. doi: 10.5603/CJ.2017.0008.

6. Tayefi M., Tajfard M., Saffar S., Hanachi P., Amirabadizadeh A.R., Esmaeily H. et al. hs-CRP is strongly associated with coronary heart disease (CHD): A data mining approach using decision tree algorithm. Comput Methods Programs Biomed. 2017 Apr;141:105109. doi: 10.1016/j.cmpb.2017.02.001

7. Danese S., de la Motte C., Reyes B.M., Sans M., Levine A.D., Fiocchi C. Cutting edge: T-cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J. Immunol. 2004; 172:2011—2015.

8. Лагута П.С., Карпов Ю.А. Применение тикагрелора у больных с острым коронарным синдромом и при чрескожном коронарном вмешательстве. Русский медицинский журнал. 2012;14:718-723. [Laguta P.S., Karpov Yu.A. The use of ticagrelor in patients with acute coronary syndrome and with percutaneous coronary intervention. Russian Medical Journal. 2012;14:718-723. (In Russ)].

9. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2014; 35:2541-2619. DOI: 10.1093/eurheartj/ehu278.

10. Krisai P., Haschke M., Buser P.T., Mueller C. Ticagrelor induced systemic inflammatory response syndrome. BMC Cardiovasc Disord. 2017;17(1):14. DOI: 10.1186/s12872-016-0443-8.

11. Sunitha S., Rajappa M., Mohan Thappa D. et al. Is the Ratio of Antibodies Against Oxidized LDL to Oxidized LDL an Indicator of Cardiovascular Risk in Psoriasis? Oman Med J. 2016;31(5):390-393. doi: 10.5001/omj.2016.78

12. Widen C., Holmer H., Coleman M., Tudor M., Ohlsson O., Sattlin S. et al. Systemic inflammatory impact of periodontitis on acute coronary syndrome. J Clin Periodontol. 2016;43(9):713-719. doi: 10.1111/jcpe.12540.

13. Нагорнев B.A., Зота Е.Г. Цитокины, иммунное воспаление и атеросклероз. Успехи соврем биологии. 1996; 6(30):320331. [Nagornev V. A., Zot E. G. Cytokines, immune inflammation and atherosclerosis. Successes are modern biology.1996; 6(3):320-331. (In Russ)].

14. Saxena K.K., Gupta B., Gopal R., Srivastava S.S., Singh R.C., Kulshrestha V.K. et al. Plasma fibrinogen anol serum enzymes: relative significance as prognostic indicator in acute myocardial infarction. J Ass Phys India 1986; 34: 641-642.

15. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997; 336: 973979. DOI: 10.1056/NEJM199704033361401

16. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998; 97: 425428.

17. Болдуева C.A., Облавицкий Д.В., Самохвалова M.B. Развитие инфаркта миокарда после изменения характера двойной антиагрегантной терапии. Клиническое наблюдение. Неотложная кардиология. 2014; 4: 16-20. [Bolduyeva S.A., Oblavitsky D. V., Samokhvalov M. V. The development of myocardial infarction after a change in the nature of dual antiplatelet therapy. Clinical observation. Urgent cardiology. 2014; 4: 16-20. (In Russ)].

18. Аверков О.В. Двойная антитромбоцитарная терапия как долгосрочное вмешательство в рамках вторичной профилактики после инфаркта миокарда: фокус на тикагрелор. Coniliummedicum 2015; 5 (17): 38-43. [Averkov O. V. Double antiplatelet therapy as a long-term intervention in the secondary prevention after myocardial infarction: focus on ticagrelor. Conilium medicum. 2015; 5(17): 38-43. (In Russ)].

19. Нечаева Г.И., Дрокина O.B., Фисун H.H. Временная антиагрегантная терапия: место тикагрелора в клинических рекомендациях. Лечащий врач. 2015; 3: 72-75. [Nechayeva G. I., Drokina O. V., Fisun N. N. Temporary antiplatelet therapy: the place of ticagrelor in clinical recommendations. Therapist. 2015; 3: 72-75. (In Russ)].

20. Stone G.W. Ticagrelor in ACS: redefining a new standart of care? Lancet 2010; 375(9711): 263-266. DOI: http://dx.doi.org/10.1016/S0140-6736(10)60070-0.

21. Thomas M.R., Outteridge S.N., Ajjan R.A., Phoenix F., Sangha G.K., Faulkner R.E. et al. Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model. Arterioscler Thromb Vasc Biol. 2015;35(12):2562-2570. DOI: 10.1161/ATVBAHA.115.306528

22. Li Zh., Li Y., Zhang T., Miao W., Su G. Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for a randomized controlled trial Trials. 2016; 17: 75. doi: 10.1186/s13063-016-1168-9.